RecruitingMyeloid MalignancyInherited Bone Marrow Failure SyndromeClonal Expansion
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
Eligible age
18+ yrs
Accepts
All genders
Locations
3 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This clinical trial tests next generation sequencing (NGS) for the detection of precursor features of pre-myeloid cancers and bone marrow failure syndromes. NGS is a procedure that looks at relevant cancer associated genes and what they do. Finding genetic markers for pre-malignant conditions may help identify patients who are at risk of pre-myeloid cancers and bone marrow failure syndromes and lead to earlier intervention.
Sponsor: Mayo Clinic
You may qualify if…
- ✓ Patients with idiopathic cytopenias of unclear significance (ICUS)
- ✓ Patients with clonal hematopoiesis of indeterminate significance (clonal hematopoiesis of indeterminate potential \[CHIP\]), including the recently described CHIP syndrome called VEXAS (vacuoles, E1 ubiquitin ligase, X chromosomal, autoimmune and somatic)
- ✓ Patients with clonal cytopenias of undetermined significance (CCUS)
- ✓ Marrow failure syndromes with myeloid malignancy predisposition - telomere dysfunction, chromosomal breakage disorders
- ✓ Germ line inherited syndromes with risk for malignant transformation - GATA2, CEBPA, ETV-6, RUNX1, JAK2, PF6, etc.
- ✓ Low risk MDS (idiopathic dysplasia of unclear significance)
- ✓ Family member of a patient with one of the above conditions
- ✓ Patient at high risk or suspected of developing one of the above conditions
You may not qualify if…
- ✕ Patients under 18 years of age
Where it's recruiting
Source: ClinicalTrials.gov · NCT02958462 · last updated 2026-02-23